. 2022 Jun 27;20:26. doi: 10.1186/s13053-022-00224-2

Table 4.

Summary of the main recommendations on screening for PC (AISP, CAPS, AGA) [66, 90, 91]

	CAPS	AGA	AISP
Target population
PJS (LKB1/STK11)	+	+	+
FAMMM (CDKN2A)	+	+	+
HBOC (BRCA1, BRCA2, PALB2)	+	+	+
LS (MLH1, MSH2, or MSH6)	+	+	+
AT (ATM)	+	+	–
FPC	+	+	+
HP (PRSS1, SPINK1, PRSS2)	?	+	+
The onset of screening (patients’ age)
PJS	40	35	30
FAMMM	40	40	30
HBOC	45 or 55^a	50^a	40^b
LS	45 or 55^a	50^a	40^b
AT	45 or 55^a	50^a	–
FPC	50 or 55^a	50^a	45^a
HP	–	40	40^b
Method of screening
MRI/MRCP	+	+	+
EUS	+	+	+
HbA1c	+
Intervals
If no abnormality	12 M	12 M	12 M
If abnormality	3 or 6 M	3 or 6 M	Mf

Abbreviations

CAPS- Cancer of the Pancreas Surveillance Consortium

AGA American Gastroenterological Association

AISP Italian Association for the Study of the Pancreas AISP

PJS Peutz -Jeghers syndrome

FAMMM Familial atypical multiple mole melanoma

HBOC Hereditary breast-ovarian cancer syndrome

LS Lynch syndrome

AT Ataxia-teleangiectasia syndrome

HP Hereditary pancreatitis

FPC Familial pancreatic cancer

M Months

Mf More frequently in high-risk patients

^a 10 years less than age of the youngest affected family member

^b 5 years less than age of the youngest affected family member